Apricus Biosciences, Inc.
11.11.2011 19:16
---------------------------------------------------------------------------
Conference Call/Webcast to be Held Tuesday, November 15, 2011 at 12:00 Noon ET
SAN DIEGO, 2011-11-11 19:16 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI) announced today that
management will hold a conference call to discuss its third quarter 2011
financial results and ongoing corporate activities on Tuesday, November 15,
2011 at 12:00 Noon ET. The Company will file its Form 10-Q for the quarter
ended September 30, 2011 on Monday, November 14, 2011.
The call can be accessed in the U.S. by dialing 877-407-0778 and outside of the
U.S. by dialing 201-689-8565 and asking the conference operator for the Apricus
Bio Conference Call. The teleconference replay will be available for one week
by dialing in the U.S. 877-660-6853 and outside of the U.S. by dialing
201-612-7415. Replay passcodes 286 and 383367 are both required for playback.
The conference call will also be Webcast live at
http://www.investorcalendar.com/IC/CEPage.asp?ID=166631. The Webcast replay
will be available for three months.
About Apricus Biosciences, Inc.
Apricus Bio, a San Diego-based, revenue-generating, biopharmaceutical company,
has leveraged the flexibility of its clinically-validated NexACT(r) drug
delivery
technology to enable multi-route administration of new and improved compounds
across numerous therapeutic classes.
Revenues and growth are driven from out-licensing of this technology for the
development and commercialization of such compounds to pharmaceutical and
biotechnology companies worldwide. In addition, the Company is seeking to
monetize its existing Rx Division product pipeline, including its first
product, Vitaros(r), approved in Canada for the treatment of erectile
dysfunction, which is currently expected to be available on the Canadian market
in 2011, as well as compounds in development from pre-clinical through Phase
III, currently focused on Sexual Dysfunction, Oncology, Dermatology,
Autoimmune, Pain, Anti-Infectives, Diabetes and Cosmeceuticals among others.
The Company is also developing its Consumer Healthcare Division by developing a
number of drugs that utilize the Company's NexACT(r) technology to comply with
the FDA's over-the-counter ('OTC') requirements, can be cleared as 510(k)
topical creams that are considered to be medical devices or approved as
Abbreviated New Drug Applications ('ANDAs') as generic drugs. The Company will
also seek to market such drugs through these similar procedures in foreign
countries.
For further information on Apricus Bio, visit http://www.apricusbio.com, and
for information on its subsidiary please visit http://www.nexmedusa.com . You
can also receive information at http://twitter.com/apricusbio and
http://facebook.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to further develop its Vitaros(r)
product for erectile dysfunction and other products and product candidates, to
have its products and product candidates approved by relevant regulatory
authorities, to successfully commercialize such products and product candidates
and to achieve its other development, commercialization and financial goals.
Readers are cautioned not to place undue reliance on these forward-looking
statements as actual results could differ materially from the forward-looking
statements contained herein. Readers are urged to read the risk factors set
forth in the Company's most recent annual report on Form 10-K, subsequent
quarterly reports filed on Form 10-Q and other filings made with the SEC.
Copies of these reports are available from the SEC's website or without charge
from the Company.
Apricus Biosciences, Inc.
Edward Cox, V.P.
Investor Relations & Corporate Development
Apricus Bio, Inc.
(858) 848-4249
ecox@apricusbio.com
Apricus Bio Investor Relations
Paula Schwartz
Rx Communications Group, LLC
(917) 322-2216
pschwartz@rxir.com
News Source: NASDAQ OMX
11.11.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Apricus Biosciences Announces Third Quarter 2011 Financial Results Conference Call
| Source: EQS Group AG